Stay updated with breaking news from Gary Waanders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
04.08.2023 - AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD)Enrollment in ongoing Phase ...
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA , a clinical-stage biopharmaceutical company pioneering precision medicine...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA with Investigational New Drug (IND) clearance for ACI-24.060Dosed first individual with Down syndrome (DS) in the DS cohort of ABATEInterim safety and immunogenicity data in Alzheimer’s disease (AD) and DS cohorts expected in H2 2023Initial PET data on amyloid plaque reduction in AD expected
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pion...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer's disease (AD)